Clinical Trial

Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients

Recruiting
View on ClinicalTrials.gov →
Summary
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-07; most recent amendment 2025-06-11.
Trial Details
NCT Number NCT06875700
Lead Sponsor University of Utah
Collaborators: National Cancer Institute (NCI), University of New South Wales, University of Michigan
Conditions Leiomyosarcoma
Enrollment 300 participants
Start Date 2024-07-09
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-13